Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMENX90)

Drug Name	PMID26077642-Compound-Figure3A Drug Info
Cross-matching ID	TTD Drug ID DMENX90

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ubiquitin carboxyl-terminal hydrolase 14 (USP14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tricyclic heterocycle derivative 4	DM9XBL4	N. A.	N. A.	Patented	[1]
BAP-15	DMOW07D	Solid tumour/cancer	2A00-2F9Z	Preclinical	[2]
IU1	DMJ0A2R	Neurodegenerative disorder	8A20-8A23	Preclinical	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ubiquitin C-terminal hydrolase UCH37 (UCHL5)	TTSX29Z	UCHL5_HUMAN	Inhibitor	[1]
Ubiquitin carboxyl-terminal hydrolase 14 (USP14)	TTVSYP9	UBP14_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
2	The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
3	Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1157-1170.